Hoechst Aktiengesellschaft

Aventis Pharma Deutschland, Gmbh

Max-planck-gesellschaft Zur Forderung Der Wissenschaften E.v.

Sanofi-a Ventis Deutschland Gmbh

Hoechst Japan Limited

Hoechst Aktiengellschaft

Heinrich Christian Englert

Dieter Mania

Hans-Jochen Lang

Joachim Kaiser

Uwe Gerlach

Heinz Gogelein

Wolfgang Linz

Jens Hartung

Bernward Scholkens

Wolfgang Scholz

Holger Heitsch

Udo Albus

Max Hropot

Erik Klaus

Heinz-Werner Kleemann

Andreas Gerhard Weichert

Heinz G&ouml;gelein

David Wettlaufer

Bansi Lal

Peter Crause

Rainer Greger

Heinz G Ogelein

Martin Bickel

Joachim Brendel

Klaus Wirth

Hans Jochen Lang

Roman Muschaweck

Reinhard Becker

Roland Utz

Hansjorg Urbach

Rainer Henning

Hiroshi Kitagawa

Denis Carniato

Volker Teetz

Jan-Robert Schwark

Tsutomu Inoue

Hermann J Gerhards

Adalbert Wagner

Stephanie Hachtel

Jean-Paul Vevert

Wulf Merkel

Mizuho Inazu

Erich F Paulus

Stefania Pfeiffer-Marek

Doris Gehring

Heinz Goegelein

Heinz-Werner Kleeman

Tobias Metzenthin

Anil Vasantrao Ghate

Masakazu Katoh

Ramanujam Rajagopalan

Florian Lang

Ryoichi Satoh

Helmut Bohn

David W Laufer

John C Ellory

Klaus Weidman

Harald Schneider

Paul-Gerhard Kibat

Ramesh Gidwani

Radha Panicker

Chinnakulandai Sankar

Karl-Heinz Lehr

David Wettlauper

John-Claude Caille

The present invention relates to piperidinesulfonylureas and piperidinesulfonylthioureas of formula I, in which A, X, R(1), R(2) and R(3) have the meanings indicated in the claims. The compounds of formula I are valuable active pharmaceutical ingredients which show in particular an inhibiting effect on ATP-sensitive potassium channels of the cardiac muscle and are suitable, for example, for the treatment of disorders of the cardiovascular system such as coronary heart disease, arrhythmias, cardiac insufficiency, cardiomyopathies or reduced contractility of the heart or for the prevention of sudden cardiac death. The invention further relates to processes for preparing the compounds of formula I, their use and pharmaceutical compositions comprising them.

Piperidinesulfonylureas and -thioureas, their preparation, their use and pharmaceutical compositions comprising them

The present invention relates to crystalline forms of the sodium salt of 5-chloro-2-methoxy-N-(2-(4-methoxy-3-methylaminothiocarbonylaminosulfonylphenyl)ethyl)benzamide, processes for their preparation, their use, and pharmaceutical preparations comprising them.

Crystalline forms of the sodium salt of 5-chloro-2-methoxy-N-(2-(4-methoxy-3-methylaminothiocarbonylaminosulfonylpenyl)ethyl)benzamide

Substituted 1-naphthoylguanidines, process for their preparation, their use as a medicament or diagnostic , and medicament containing them

Acylaminoalkyl-substituted benzenesulfonamide derivatives, their preparation, their use and pharmaceutical preparations comprising them

Heteroarylacryloylaminoalkyl-substituted benzenesulfonamide derivatives, their preparation, their use and pharmaceutical preparations comprising them

Use of benzenesulfonyl(thio)ureas for the treatment and prophylaxis of dysfunctions of the autonomous nervous system and use of benzenesulfonyl(thio)ureas in combination with beta-receptors blockers

Novel 2,5-substituted benzolsulfonyl ureas and thioureas of formula (I) as illustrated in the disclosure. The compounds are useful active ingredients for medicaments. The compounds of formula (I) act as inhibitors on ATP-sensitive potassium canals and are suitable for the treatment of cardiovascular disorders, especially the treatment of arrhythmias, prevention of sudden death from heart disease or affect diminished contractility of the heart. The invention also relates to methods for producing compounds of formula (I), the use thereof and pharmaceutical preparations containing said compounds.

2,5-substituted benzolsulfonylureas and thioureas methods for the production thereof use thereof and pharmaceutical preparations containing the same

Cinnamoylaminoalkyl-substituted benzenesulfonamide derivatives, processes for their preparation, their use, and pharmaceutical preparations comprising them

Substituted benzenesulfonylureas and thioureas-process for their preparation and their use as pharmaceuticals

Benzenesulfonylureas and -thioureas of the formula I ##STR1## where R(1) is H or (fluoro)methyl, R(2) is H, Hal or (fluoro)(mercapto)alk(ozy)yl, E is O or S; Y is --[CR(3).sub.2 ].sub.n --, where R(3)=H or alkyl and n=1-4, X is H, Hal or alkyl and Z in Hal, NO.sub.2 or alk(yl)oxy, are described. The compounds I are used for treatment of disturbances in cardiac rhythm and prevention of sudden cardiac death caused by arrhythmia, and can therefore be used as antiarrhythmics. They are particularly suitable for those cases where arrhythmias are a consequence of a narrowing of a coronary vessel, such as angina pectoris or acute cardiac infarction.

Substituted benzenesulfonylureas and -thioureas--process for their

Substituted 2-naphthoylguanidines, process for their preparation, their use as a medicament or diagnostic, and medicament containing them Substituted 2-naphthoylguanidines of the formula I ##STR1## having the meanings indicated in claim 1 for R1 to R8, are suitable as antiarrhythmic pharmaceuticals having a cardioprotective component for infarct prophylaxis and infarct treatment and for the treatment of angina pectoris. They also preventively inhibit the pathophysiological processes in the formation of ischemically induced damage, in particular in the production of ischemically induced cardiac arrhythmias.

Substituted 2-naphthoylguanidines, process for their preparation, their

This invention relates to substituted benzenesulfonylureas and -thioureas, processes for their preparation and use of pharmaceutical preparations based on these compounds, and medicaments containing them. Substituted benzenesulfonylureas and -thioureas of the formula I ##STR1## exhibit effects on the cardiovascular system.

Substituted benzenesulfonylureas and-thioureas, processes for their

3-amidochromanylsulfonyl(thio)ureas of the formula (I): ##STR1## which are valuable pharmaceutically active compounds for the treatment of disturbances of the cardiovascular system, in particular for the treatment of arrhythmias, for preventing sudden cardiac death or for influencing a reduced contractility of the heart, and processes for their preparation, their use and pharmaceutical preparations comprising them.

3-amidochromanylsulfonyl(thio)ureas, processes for their preparation,

Substituted chromanylsulfonyl(thio)ureas, processes for their preparation, their use in pharmaceutical preparations, and pharmaceutical preparations comprising them Chromanylsulfonyl(thio)ureas of the formula I ##STR1## are useful pharmaceuticals for the treatment of cardiac arrhythmias and for the prevention of sudden heart death due to arrhythmia. They can be used as antiarrhythmics and are suitable for the prevention of sudden heart death, for the treatment of cardiac insufficiency and also heart failure as a result of the effects of shock.

Substituted chromanysulfonyl (thio) ureas, processing for their

Growing community of inventors

Hofheim, Germany

Heinrich Christian Englert